213 related articles for article (PubMed ID: 36422199)
21. Implications of glutathione-S transferase P1 in MAPK signaling as a CRAF chaperone: In memory of Dr. Irving Listowsky.
Niitsu Y; Sato Y; Takayama T
Proc Jpn Acad Ser B Phys Biol Sci; 2022; 98(2):72-86. PubMed ID: 35153270
[TBL] [Abstract][Full Text] [Related]
22. Expression of genes of glutathione transferase isoforms GSTP1-1, GSTA4-4, and GSTK1-1 in tumor cells during the formation of drug resistance to cisplatin.
Kalinina EV; Berozov TT; Shtil AA; Chernov NN; Glasunova VA; Novichkova MD; Nurmuradov NK
Bull Exp Biol Med; 2012 Nov; 154(1):64-7. PubMed ID: 23330092
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer.
Dong X; Sun R; Wang J; Yu S; Cui J; Guo Z; Pan X; Sun J; Yang J; Pan LL
Biochem Pharmacol; 2020 Dec; 182():114289. PubMed ID: 33080187
[TBL] [Abstract][Full Text] [Related]
24. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
25. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract][Full Text] [Related]
26. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance.
Harbottle A; Daly AK; Atherton K; Campbell FC
Int J Cancer; 2001 Jun; 92(6):777-83. PubMed ID: 11351295
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
28. Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Zhu FS; Chen XM; Huang ZG; Wang ZR; Zhang DW; Zhang X
J Dig Dis; 2010 Feb; 11(1):34-42. PubMed ID: 20132429
[TBL] [Abstract][Full Text] [Related]
29. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study.
Oldenburg J; Kraggerud SM; Brydøy M; Cvancarova M; Lothe RA; Fossa SD
J Transl Med; 2007 Dec; 5():70. PubMed ID: 18162130
[TBL] [Abstract][Full Text] [Related]
30. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
31. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
32. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer.
Alharbi M; Zuñiga F; Elfeky O; Guanzon D; Lai A; Rice GE; Perrin L; Hooper J; Salomon C
Endocr Relat Cancer; 2018 Dec; 25(12):R663-R685. PubMed ID: 30400025
[TBL] [Abstract][Full Text] [Related]
33. Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells.
Huang G; Mills L; Worth LL
Mol Cancer Ther; 2007 May; 6(5):1610-9. PubMed ID: 17513610
[TBL] [Abstract][Full Text] [Related]
34. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
35. Selective inhibitors of glutathione transferase P1 with trioxane structure as anticancer agents.
Bräutigam M; Teusch N; Schenk T; Sheikh M; Aricioglu RZ; Borowski SH; Neudörfl JM; Baumann U; Griesbeck AG; Pietsch M
ChemMedChem; 2015 Apr; 10(4):629-39. PubMed ID: 25694385
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.
Saburi A; Kahrizi MS; Naghsh N; Etemadi H; İlhan A; Adili A; Ghoreishizadeh S; Tamjidifar R; Akbari M; Ercan G
J Ovarian Res; 2022 Jul; 15(1):81. PubMed ID: 35799305
[TBL] [Abstract][Full Text] [Related]
37. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
38. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
39. Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells.
Fan C; Yuan S; Zhang Y; Nie Y; Xiang L; Luo T; Xi Q; Zhang Y; Gu Z; Wang P; Zhou H
Biochem Biophys Rep; 2024 Mar; 37():101639. PubMed ID: 38288281
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression.
Gao P; Yang X; Xue YW; Zhang XF; Wang Y; Liu WJ; Wu XJ
Cancer; 2009 Jul; 115(14):3222-32. PubMed ID: 19484794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
